Better Adherence With New Oral Anticoagulant in Atrial Fibrillation : Effectiveness of a Personalized Education Program

• Status: Completed
• Trial end date: 2016-05-06
• Target enrollment: 0
• Participant gender: All

Summary

This study is multicentric, single-blind, and interventional with a randomization into two parallel arm, between a standard of care information and an additional information of the patient, with a 12 month follow up.

The aim of this study is to evaluate the effectiveness of a personalized information program versus information provided from standard of care in patients taking Xarelto for Stroke Prevention in Atrial Fibrillation.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Montpellier
• Treatments: Rivaroxaban

Criteria

Inclusion Criteria:

• All patients treated with rivaroxaban chronically, (atrial fibrillation non-valvular under current AMM) for less than one year whatever anti vitamin K treatment history

• Affiliate or beneficiary of a social security system.

• Patient who formulated its "does not oppose" to participate in this research

• Age higher than or equal to 18 years

Exclusion Criteria:

• Opposition to participation

• Patient don't understand french language

• Patient does not have responsibility for the management of treatment (treatment administered by a nurse at home, or by caregivers)

• Tutorship or curatoship

• Law-protected patient

• Pregnant women or breast-feeding